Navigation Links
Gene assay to help to predict lung cancer treatment resistance
Date:8/26/2009

The genes that may contribute to drug resistance in non-small cell lung cancer (NSCLC) can be predicted. Researchers writing in the open access journal BMC Cancer found good correlation between genes believed to be involved in drug sensitivity and resistance and actual in vitro chemosensitivity.

Ian Cree, from Queen Alexandra Hospital, Portsmouth, UK, led a team of researchers who assessed the chemosensitivity of a series of 49 NSCLC tumors and compared this with quantitative expression of putative resistance genes measured by RT-PCR. He said, "There was considerable heterogeneity between tumors, and while this showed no direct correlation with individual gene expression, there was strong correlation of multi-gene signatures for many of the single chemotherapy agents and combinations tested. This may allow the definition of predictive signatures to guide individualized chemotherapy in lung cancer".

The researchers tested docetaxel, cisplatin, gemcitabine and combinations of the agents on tumour cells taken from 49 fresh NSCLC samples. There were considerable differences between tumors in their sensitivity to individual agents and combinations, though the combination of cisplatin + gemcitabine was usually the most active.

When these results were compared to the gene expression in the tumors, Cree and his colleagues were able to identify a number of patterns, especially in chemosensitivity to combinations of treatments. Cree said, "The genes identified in this study fall into several categories, linked with much studied mechanisms such as metabolism within the cell, membrane drug pumps, and DNA repair, but also with apoptosis, suggesting that the general susceptibility of the cell to undergo this process may be an important determinant of tumor chemosensitivity, outweighing more specific mechanisms".


'/>"/>

Contact: Graeme Baldwin
graeme.baldwin@biomedcentral.com
44-020-319-22165
BioMed Central
Source:Eurekalert

Page: 1

Related medicine news :

1. Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
2. AutoGenomics Receives FDA Clearance for its INFINITI(TM) Warfarin Assay
3. PATHFAST(R): Rapid Whole Blood Immunoassay Analyzer from Polymedco
4. Clarient Partners With Joint Venture Hospital Laboratories to Offer Pathologists Wide Array of Cancer Assays
5. Multiple Independent Studies Report on Use of Cylexs Immune Cell Function Assay in Postoperative Monitoring of Kidney, Liver, and Heart Transplant Recipients
6. Monogram Biosciences Announces Immediate Availability of Enhanced Sensitivity Trofile(TM) HIV Tropism Assay
7. Data Published in Anticancer Research Show ChemoFx(R) Assay Results Correlate With Outcomes in Breast Cancer
8. Monogram Announces Commercial Availability of the HERmark(TM) Breast Cancer Assay
9. Associates of Cape Cod (ACC) and MDS Analytical Technologies Collaborate to Offer a More Robust LAL Endotoxin Assay Platform
10. Battelle to Perform Verification Studies of IntelligentMDxs Proprietary Molecular Diagnostic Assay Process
11. Development of Novel Assays Vital for the European Immunoassay Diagnostics Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... The ... the 2017 Public Leadership in Neurology Award (PLINA). The couple joins a prestigious ... Bruschi, Vice President Walter Mondale, actor Michael J. Fox and former U.S. Attorney ...
(Date:4/27/2017)... ... ... Are you investing in the safety of your friends and family? Each ... While most of us assume this type of accident will never happen to us, ... taking the time to learn how to respond effectively or prevent these accidents from ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... to announce the ATA 2017 President’s Awards recipients, comprised of organizations and ... healthcare delivery. , The ATA 2017 President’s Awards recognize individuals and ...
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may ... pelvic conditions and has helped many women become pregnant upon treating their diagnosis. ... office-based and simple outpatient evaluations. We can provide the necessary information to ...
(Date:4/26/2017)... ... April 26, 2017 , ... Bioclinica® ... sponsors and CROs to speed clinical development, has released the industry’s only ... Bioclinica AGILE RTSM provides seamless clinical supply forecasting and management together ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... -- Research and Markets has announced the ... Prospects: Addressing Production Complexities Through Risk Management and Quality ... ... and Market Prospects: Overcoming Production Complexities Through Risk Management ... the current trends in the global biosimilars market, with ...
(Date:4/20/2017)... Inc ., a digital health company focused on modernizing and ... $25 million in Series B funding led by Qiming US ... Seattle that is part of a broader family ... included participation from SR One , who led ZappRx,s ... Google Ventures). As part of the financing, Mark McDade ...
(Date:4/20/2017)... , April 20, 2017 NeuroVive Pharmaceutical ... today announced positive preclinical results demonstrating anti-fibrotic ... for non-alcoholic steatohepatitis (NASH), in an additional ... NV556 has previously shown similar anti-fibrotic ... Today, NeuroVive,s scientists present novel data demonstrating ...
Breaking Medicine Technology: